BIOGEN INC. Accounts Receivable, Allowance for Credit Loss, Current
BIOGEN INC. (BIIB) had Accounts Receivable, Allowance for Credit Loss, Current of $3.00 million as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent · last filed 2026-04-29
- 2026-03-31: Accounts Receivable, Allowance for Credit Loss, Current $3.00M.
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss, Current $3.00M.
- 2025-09-30: Accounts Receivable, Allowance for Credit Loss, Current $2.20M.
- 2025-06-30: Accounts Receivable, Allowance for Credit Loss, Current $2.20M.
| Period end | Accounts Receivable, Allowance for Credit Loss, Current |
|---|---|
| 2026-03-31 | $3.00M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $3.00M 10-Q · filed 2026-04-29 |
| 2025-09-30 | $2.20M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $2.20M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $2.20M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $2.20M 10-K · filed 2026-02-06 |
| 2024-09-30 | $2.40M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $2.40M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $2.40M 10-Q · filed 2024-04-24 |
| 2023-12-31 | $2.40M 10-K · filed 2025-02-12 |
| 2022-12-31 | $2.30M 10-K · filed 2024-02-14 |
| 2011-12-31 | $57.52M 10-K · filed 2012-02-03 |
| 2010-12-31 | $54.92M 10-K · filed 2012-02-03 |
| 2009-12-31 | $43.82M 10-K · filed 2011-02-04 |
| 2008-12-31 | $32.05M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |